Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Jacques

Showing results (261-270 of 271) with videos related to

Pageof 28
Sort By:
Lasers in Surgery and Medicine|January 18, 2019
Hyperspectral imaging in automated digital dermoscopy screening for melanomaAnna-Marie Hosking, Brandon J Coakley, Dorothy Chang, et al.
Cancer Treatment and Research|November 26, 2015
Methods of Melanoma DetectionSancy A Leachman, Pamela B Cassidy, Suephy C Chen, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2010
Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitorsHu Liu, Cyrille Kuhn, Frederic Feru, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool CompoundLorna H Mitchell, Allison E Drew, Scott A Ribich, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Cell Reports|January 17, 2019
Modeling Tumor Phenotypes In Vitro with Three-Dimensional BioprintingEllen M Langer, Brittany L Allen-Petersen, Shelby M King, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2009
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patientsKetan S Gajiwala, Joe C Wu, James Christensen, et al.
Scientific Reports|December 23, 2017
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E Drew, Oscar Moradei, Suzanne L Jacques, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Nature Chemical Biology|April 28, 2015
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsElayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, et al.
Pageof 28

Showing results (261-270 of 271) with videos related to

Sort By:
Pageof 28
Lasers in Surgery and Medicine|January 18, 2019
Hyperspectral imaging in automated digital dermoscopy screening for melanomaAnna-Marie Hosking, Brandon J Coakley, Dorothy Chang, et al.
Cancer Treatment and Research|November 26, 2015
Methods of Melanoma DetectionSancy A Leachman, Pamela B Cassidy, Suephy C Chen, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2010
Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitorsHu Liu, Cyrille Kuhn, Frederic Feru, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool CompoundLorna H Mitchell, Allison E Drew, Scott A Ribich, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Cell Reports|January 17, 2019
Modeling Tumor Phenotypes In Vitro with Three-Dimensional BioprintingEllen M Langer, Brittany L Allen-Petersen, Shelby M King, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2009
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patientsKetan S Gajiwala, Joe C Wu, James Christensen, et al.
Scientific Reports|December 23, 2017
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E Drew, Oscar Moradei, Suzanne L Jacques, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Nature Chemical Biology|April 28, 2015
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsElayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, et al.
Pageof 28